Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial

Andrew Blauvelt, Richard G. Langley, Jean Philippe Lacour, Darryl Toth, Vivian Laquer, Stefan Beissert, Andreas Wollenberg, Pedro Herranz, Andrew E. Pink, Ketty Peris, Stine Fangel, Le Gjerum, Joshua Corriveau, Hidehisa Saeki, Richard B. Warren, Eric Simpson, Kristian Reich

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Fingerprint

Dive into the research topics of 'Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial'. Together they form a unique fingerprint.

Medicine & Life Sciences